Document Type : Original Article(s)

Authors

1 Department of Hematology and Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Hematology and Oncology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

3 Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

4 Water and Electrolytes Research Center, Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran

5 School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

6 Department of Hematology and Oncology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Cisplatin (CP) is a potent antineoplastic agent in the treatment of wide a range of cancers, but it is accompanied with nephrotoxicity, a major limiting side effect. The aim of the present study was to evaluate the possible protective effect of vitamin E in the prevention of CP-induced nephrotoxicity.
Method: In this randomized clinical trial, a total of 51 patients treated with CP chemotherapy were randomly assigned to receive vitamin E supplementation (400 Iu/ daily) (N=26) or placebo (N=25). Serum creatinine, glomerular filtration rate (GFR), and neutrophil gelatinase-associated lipocalin were measured prior to each chemotherapy cycle and one month after the cessation of the cycles.
Result: Compared to the baseline, a significant decrease was observed in the blood levels of neutrophil gelatinase-associated lipocalin and serum creatinine in the vitamin E group (P=0.001). GFR was not reduced in the vitamin E group (P=0.001), and vitamin E was generally tolerated well.
Conclusion: Our findings indicated that vitamin E exert protective effects against CP-induced nephrotoxicity, a finding which requires larger studies for confirmation.

Keywords